Biodesix, Inc. Common Stock (BDSX) Stock Price
BDSXStock
$23.66+240.43%52W
Market Cap$249.64M
P/E—
PEG Ratio—
Div yield—
Beta0.63
BDSX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)84.99%
Price vs S&P 500 (4W)-15.45%
VGM Score58.64
BDSX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.90 | -$0.71 | +21.36%(+$0.19) | |
| Q1 2026 | -$1.10 | -$0.81 | +26.09%(+$0.29) | |
| Q4 2025 | -$0.87 | -$0.49 | +43.42%(+$0.38) | |
| Q3 2025 | -$1.51 | -$1.16 | +22.97%(+$0.35) | |
| Q2 2025 | -$1.37 | -$1.60 | -17.07%(-$0.23) |
BDSX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.18
4.15
4.15
4.15
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
BDSXBiodesix, Inc. Common Stock | D | B | B | — | 34.5% | -20.0% | -164.9% | $23.66 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
About Biodesix, Inc. Common Stock
Biodesix is a lung-focused diagnostic company that provides blood-based testing services for lung cancer and COVID-19. The company generates revenue through two primary channels: direct diagnostic testing services and partnerships with biopharmaceutical companies for clinical trial diagnostics and companion diagnostic development. This dual-revenue model positions Biodesix at the intersection of clinical diagnostics and drug development, creating diverse market opportunities.